Medicina, Dermatología y Toxicología
Departamento
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (4)
2024
-
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
Pain and Therapy, Vol. 13, Núm. 3, pp. 557-576
2023
-
Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine
Neurology and Therapy, Vol. 12, Núm. 4, pp. 1319-1334
2022
-
Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain
Patient Preference and Adherence, Vol. 16, pp. 3291-3302
-
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
Journal of Headache and Pain, Vol. 23, Núm. 1